About this trial
Visual impairment, particularly from glaucoma and retinal dystrophies, significantly hinders mobility and increases the risk of falls, leading to decreased independence and mental health challenges. Current low-vision assistive technologies primarily focus on near-task magnification for reading, leaving a critical gap in tools designed to assist with real-world navigation and peripheral vision loss. To address this, the proposed research evaluates Meta AI glasses, which offer real-time scene narration and object recognition, integrated with the Be My Eyes network. The study hypothesizes that this wearable AI technology will improve ambulation, orientation, and overall quality of life for patients, providing a functional solution for mobility that traditional devices lack.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Confirmed diagnosis of glaucoma, retinal dystrophy, or another condition associated with legal blindness.
Presence of documented irreversible vision loss
No surgical or laser procedures in the last 6 months
Visual field worse than 12db or poor visual acuity 20/400 or worse
Disqualifiers
Has no access to telephone
Unable to speak English
Has previously received comprehensive low vision services
Trial design
Single group
Treatments tested in this trial
Meta AI Glasses
Other interventionMeta AI glasses in patients with low vision
Control
Other intervention25 Patients will continue receiving standard care and will not receive the Meta AI glasses during the study period.
Treatment groups
Trial outcomes
Primary outcomes
patient-reported vision-targeted quality of life
The primary outcome will be change in patient-reported vision-targeted quality of life, measured using the National Eye Institute Visual Function Questionnaire - 25 item (NEI VFQ-25).
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: